Drug therapy and vascular devices used by patients hospitalized for COVID-19: a descriptive study / Terapia medicamentosa e dispositivos vasculares utilizados por doentes hospitalizados para a COVID-19: um estudo descritivo

• Autor(a) principal: Gomes, Helena Ferraz
• Data de Publicação: 2021
• Outros Autores: Pires, Bruna Maiara Ferreira Barreto, Andrade, Priscila Cristina da Silva Thiengo, Gomes, Antonio Marcos Tosoli, Souza, Norma Valéria Dantas de Oliveira, Carvalho, Eloá Carneiro, Kubota, Thais Mayerhofer, Faria, Cristiene, Leite, Dayana Carvalho, de Lima, André Herdy Afonso Alves, Messias, José Augusto, Santana, Monique Barreto, de Albuquerque, Denilson Campos, Oliveira, Denize Cristina, Peixoto, Mauricio Cupello, Silva, Pedro de Jesus, Behring, Lilian Prates Belem, de Mello, Livia Fajin, da Costa, Carolina Cabral Pereira, das Merces, Magno Conceição, de Almeida, Luana Ferreira, de Paula, Vanessa Galdino, Bittencourt, Morena Peres, Oliveira, Brenda Gratielle, dos Santos, Vitoria Rocha, Peres, Ellen Marcia
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Health Review
• Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/41501
• topic: Coronavirus Infections; Pharmaceutical Preparations; Peripheral Catheterization; Central Venous Catheterization; COVID-19.

To describe drug therapy and types of vascular access adopted in the treatment of patients with COVID-19 and admitted to the clinical wards of a university hospital, a referential institution for COVID-19 in Rio de Janeiro, Brazil. Descriptive, retrospective documentary study with a quantitative approach. The sample consisted of 243 electronic medical records from hospitalized patients with a laboratory-confirmed diagnosis of COVID-19, between April and June 2020. The selection of participants took place by intentional non-probabilistic sampling. Peripheral venous access was the mostly applied in 83.5% of the patients. The mostly used classes of drugs were analgesics, (81.9%), followed by antiemetics (70.4%), and antihypertensives (51.9%). For medications directed to COVID-19, azithromycin, oseltamivir, ceftriaxone, and hydroxychloroquine stands out with 67.5%, 58.8%, 50.2% and 27.2%, respectively.  Regarding the treatment directed to COVID-19, the medications mostly taken were azithromycin and hydroxychloroquine, justified to a large extent by being recommended by the Ministry of Health in the treatment, according to signs and symptoms (Brazil, 2020).  Patients treated with the medications described had good recovery from the clinical condition. Thus, studies based on randomized clinical trials are suggested to prove the efficacy of drug therapies, including their combination.